Overview

Inaticabtagene Autoleucel Injection in the Treatment of Autoimmune Hemolytic Anemia After Three or More Lines of Therapy

Status:
NOT_YET_RECRUITING
Trial end date:
2028-03-30
Target enrollment:
Participant gender:
Summary
This is a multicenter, open-label, single-arm Phase I clinical trial to evaluate the safety and tolerability of Inaticabtagene Autoleucel Injection treatment in autoimmune hemolytic anemia that has failed at least three lines of treatment.
Phase:
PHASE1
Details
Lead Sponsor:
Juventas Cell Therapy Ltd.